Related Experiment Video
Updated: Mar 15, 2026

Improving IV Insulin Administration in a Community Hospital
Published on: June 11, 2012
Efficacy and Management of Automated Insulin Delivery Systems Perioperatively in Type 1 Diabetes: A Scoping Review
Balwinder Ruprai1, Sarah Catania1, Vanesa Berati1
1Department of Medicine, Western University, London, Ontario, Canada.
Abstract:
Individuals with type 1 diabetes require careful perioperative management to minimize risks and optimize outcomes. Automated insulin delivery (AID) systems have demonstrated efficacy in improving glycemic management in outpatient settings. However, the safety and effectiveness of their use during surgery remains unclear. We aimed to synthesize the existing literature evaluating the perioperative use of AID systems in individuals with type 1 diabetes undergoing surgical procedures. A comprehensive search of PubMed, Ovid/MEDLINE, and CINAHL was conducted through May 20, 2025. Eligible studies included adults or children with type 1 diabetes undergoing surgery using AID systems with reported glycemic outcomes. Data were extracted from cohort studies, case reports, and expert guidance documents. Screening and data extraction were performed in Covidence by 3 independent reviewers. Sixteen studies were included: 2 observational cohorts, 9 case reports/series, 2 reviews, 1 retrospective study, 1 randomized controlled trial, and 1 expert guidance document. Across all studies, continuation of AID systems perioperatively was associated with long-duration time in range, minimal hypoglycemia, and no severe adverse events such as diabetic ketoacidosis. Technical concerns included continuous glucose monitoring signal interference from medications or surgical equipment. Expert guidance emphasized individualized planning, intraoperative monitoring, and device-specific considerations. Preliminary evidence suggests that perioperative continuation of AID systems is safe and feasible in select individuals with type 1 diabetes. However, despite promising glycemic outcomes, the current literature is limited to small-scale, mostly observational data. Larger prospective studies are needed to validate safety, inform standardized protocols, and support widespread clinical adoption.
More Related Videos
11:31High-Efficiency Generation of Antigen-Specific Primary Mouse Cytotoxic T Cells for Functional Testing in an Autoimmune Diabetes Model
Published on: August 16, 2019
10:03Bioluminescent Monitoring of Graft Survival in an Adoptive Transfer Model of Autoimmune Diabetes in Mice
Published on: November 18, 2022
Related Concept Videos
Insulin: Dosing Regimen and Adverse Effects
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin Formulations: Types and Delivery
Short-acting insulins are divided into...
Diabetes Mellitus: Overview and Type I Subtype
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes Mellitus: Type 2 and Gestational
Parenteral Drug Delivery Systems: Injectables, Implants, and Infusion Devices